Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

Archives

Author Archives: Cathy Wilson
Sep 12, 2016Cathy WilsonNews

MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox in Canada

12 September 2016 MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada (Pickering, Canada and Victoria, Australia, 12 September 2016) Medical Developments International Limited (MDI) (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in […]

Read more
Sep 9, 2016Cathy WilsonNews

Penthrox receives regulatory approval in the UAE

9 September 2016 ASX ANNOUNCEMENT Penthrox receives regulatory approval in the UAE Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received regulatory approval and the Marketing Authorisation (MA) for the sale of Penthrox in the United Arab Emirates (UAE). The CEO of MVP, Mr. Sharman said: “Penthrox has been supplied […]

Read more
Sep 5, 2016Cathy WilsonNews

ASX Announcement – Licensing deal for Korea

6 September 2016 ASX ANNOUNCEMENT Licensing deal for Korea Medical Developments International Limited (MDI) (ASX: MVP) is delighted to announce it has reached agreement with BL&H Co Ltd (BL&H) for the exclusive distribution rights of Penthrox® in Korea. The transaction includes upfront and milestone payments of AUD $1.2 million and BL&H will manage the registration, […]

Read more
Aug 17, 2016Cathy WilsonNews

FY16 Full Year Results

18 August 2016 ASX ANNOUNCEMENT FY16 Full Year Results For details relating to the full ASX Release, please click on the following link FY16 Full Year Results

Read more
Aug 11, 2016Cathy WilsonNews

European Penthrox Update

12 August 2016 ASX ANNOUNCEMENT European Penthrox Update. Medical Developments International Limited (ASX: MVP) advises that the roll out and acceptance of Penthrox in the United Kingdom, Republic of Ireland and the EU is going to plan. CEO of Medical Developments, Mr. John Sharman said: “We have just received our first order from Mundipharma for […]

Read more
Aug 9, 2016Cathy WilsonNews

USA Penthrox Update & USA Respiratory Update

9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America.  On the basis of the FDA’s written response, MVP […]

Read more
Aug 9, 2016Cathy WilsonNews

USA Penthrox Update & USA Respiratory Update

9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America.  On the basis of the FDA’s written response, MVP […]

Read more
Jun 14, 2016Cathy WilsonNews

Licensing deal for Canada

14 June 2016   ASX ANNOUNCEMENT   Licensing deal for Canada Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed a Term Sheet with a significant pharmaceutical company to distribute Penthrox® in Canada. The Term Sheet includes upfront and milestone payments of CAD $3.0 million. For more details please click on […]

Read more
Apr 6, 2016Cathy WilsonNews

Bell Potter and Patersons Initiate Coverage on MVP

Bell Potter and Patersons has recently initiated coverage on Medical Developments International (ASX:MVP).  For a copy of the analyst’s report which has market analysis, buy recommendation and price target, please contact Bell Potter and Patersons respectively

Read more
Feb 18, 2016Cathy WilsonNews

Half Year Report 2015-16

18 February 2016 HALF YEAR REPORT 2015-2016 For a copy of the Half Year Report 2015-16, please click on the following link – Half Year Report 2015-16

Read more
Page 3 of 5 : 12345

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter